RESUMO
Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.
Assuntos
Transtornos de Enxaqueca , Neurologia , Humanos , Cefaleia , Transtornos de Enxaqueca/prevenção & controle , Transtornos de Enxaqueca/tratamento farmacológico , Consenso , ÁustriaRESUMO
Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.
Assuntos
Transtornos de Enxaqueca , Cefaleia do Tipo Tensional , Humanos , Cefaleia , Transtornos de Enxaqueca/prevenção & controle , Sociedades , ÁustriaAssuntos
Regulação da Temperatura Corporal , Febre/terapia , Hipotermia Induzida/métodos , Transtornos de Enxaqueca/terapia , Sepse/terapia , Febre/diagnóstico , Febre/fisiopatologia , Humanos , Hipotermia Induzida/efeitos adversos , Transtornos de Enxaqueca/diagnóstico , Transtornos de Enxaqueca/fisiopatologia , Sepse/diagnóstico , Sepse/fisiopatologia , Resultado do TratamentoAssuntos
Clostridium tetani , Cuidados Críticos , Tétano/terapia , Idoso de 80 Anos ou mais , Feminino , HumanosRESUMO
OBJECTIVES: Intraventricular catheters impregnated with silver nanoparticles are developed to reduce catheter-associated infections in cerebrospinal fluid (CSF) drainages. Silver released from these new catheters should have an anti-microbacterial effect. This study examines the silver ion release and a potential effect of bacterial growth in an in vitro experiment. METHODS: Seven original silver-coated ventricle catheters were rinsed thoroughly with an artificial CSF for 6 days. The collecting containers were replaced every 24 hours. In these samples, ion concentrations of silver were determined via trace analysis through atomic absorption spectroscopy. Furthermore, a bacterial growth was conducted on silver-impregnated and non-impregnated catheters. RESULTS: In none of the samples, a concentration of silver ions could be detected. For Staphylococcus aureus, a slightly decreased bacterial growth could be observed with silver-impregnated catheters. DISCUSSION: There is no risk of a toxic effect due to silver release into the CSF. However, the in vivo antibacterial effect has to be further investigated. We recommend clinical trials to prove the oligodynamic and anti-microbacterial effects of silver-impregnated ventricular catheters.
Assuntos
Bactérias/efeitos dos fármacos , Cateteres de Demora , Líquido Cefalorraquidiano/microbiologia , Nanopartículas Metálicas , Prata/farmacologia , Tensoativos/farmacologia , Animais , Bactérias/crescimento & desenvolvimento , Aderência Bacteriana/efeitos dos fármacos , Cateteres de Demora/microbiologia , Líquido Cefalorraquidiano/fisiologia , Técnicas In Vitro , Espectrofotometria Atômica/métodosAssuntos
Infecções por Bartonella/complicações , Bartonella henselae/patogenicidade , Encefalite/etiologia , Encefalite/microbiologia , Adolescente , Infecções por Bartonella/diagnóstico por imagem , Bartonella henselae/genética , Bartonella henselae/isolamento & purificação , Progressão da Doença , Encefalite/diagnóstico por imagem , Feminino , Humanos , Tomografia Computadorizada de Emissão de Fóton Único/métodosRESUMO
OBJECTIVE: To determine the safety and efficacy of a novel intravascular cooling device (Cool Line catheter with Cool Gard system) to control body temperature (temperature goal <37 degrees C) in neurologic intensive care patients. DESIGN: A prospective, uncontrolled pilot study in 51 consecutive neurologic intensive care patients. SETTING: A neurologic intensive care unit at a tertiary care university hospital. PARTICIPANTS: Patients were 51 neurologic intensive care patients with an intracranial disease requiring a central venous catheter due to the primary (intracranial) disease. We excluded patients under the age of 19 yrs and those with active cardiac arrhythmia, full sepsis syndrome, bleeding diathesis and infection, or bleeding at the site of the intended catheter insertion. Male to female ratio was 31:20, and the median age was 55 yrs (range, 24-85 yrs). Forty-four of 51 patients (86.3%) had an initial Glasgow Coma Scale score of 3, three patients had a Glasgow Coma Scale score of 9, one patient presented with an initial Glasgow Coma Scale score of 11, two patients had an initial Glasgow Coma Scale score of 13, and one patient had an initial Glasgow Coma Scale score of 15. The mean initial tissue injury severity score was 45.1 and the median initial tissue injury severity score 45.0 (range, 19-70). INTERVENTIONS: Patients were enrolled prospectively in a consecutive way. Within 12 hrs after admission, the intravascular cooling device (Cool Line catheter) was placed, the temperature probe was located within the bladder (by Foley catheter), and the Cool Gard cooling device was initiated. This Cool Gard system circulates temperature-controlled sterile saline through two small balloons mounted on the distal end of the Cool Line catheter. The patient's blood is gently cooled as it is passed over the balloons. The Cool Gard system has been set with a target temperature of 36.5 degrees C. The primary purpose and end point of this study was to evaluate the cooling capacity of this intravascular cooling device. Efficacy is expressed by the calculation formula of fever burden, which is defined as the fever time product ( degrees C hours) under the fever curve. MEASUREMENTS AND MAIN RESULTS: The cooling device was in operation for a mean of 152.4 hrs. The ease of insertion was judged as easy in 42 of 51 patients; in a single patient, the catheter was malpositioned within the jugular vein, requiring early removal. The rate of infectious and noninfectious complications (nosocomial pneumonia, bacteremia, catheter-related ventriculitis, pulmonary embolism, etc.) was comparable to the rate usually observed in our neurologic intensive care patients with such severe intracranial diseases. The total fever burden within the entire study period of (on average) 152.4 hrs was 4.0 degrees C hrs/patient, being equivalent to 0.6 degrees C hrs/patient and day. Thirty of 51 patients showed an elevation of the body temperature (>37.9 degrees C) within 24 hrs after termination of the cooling study. One awake patient (subarachnoid hemorrhage, Glasgow Coma Scale score 15) experienced mild to moderate shivering throughout the entire period of 7 days. The mortality rate was 23.5%. CONCLUSION: This novel intravascular cooling device (Cool Line catheter and Cool Gard cooling device) was highly efficacious in prophylactically controlling the body temperature of neurologic intensive care patients with very severe intracranial disease (median Glasgow Coma Scale score, 3-15). Morbidity and mortality rates were consistent with the ranges reported in the literature for such neurologic intensive patients.